Quantcast

Latest Apoptosis Stories

2014-03-18 23:26:16

An international team of researchers say CARP-1 Functional Mimetics (CFMs) triggered the death of mesothelioma cells and blocked their ability to spread in laboratory tests. Raleigh, NC (PRWEB) March 18, 2014 Cancer Monthly is reporting on a newly-published study suggesting that compounds called CFMs might offer a better way to fight the treatment-resistant cancer, malignant pleural mesothelioma. The study entitled “CARP-1 Functional Mimetics Are a Novel Class of Small Molecule...

2014-03-14 23:04:14

Findings Shed Light On Cell Death Process, Drug's Toxicity Charlottesville, VA (PRWEB) March 14, 2014 A new discovery about how dying cells are removed from the body could have an unexpected and important benefit: allowing doctors to rehabilitate a powerful antibiotic now deemed too toxic for human use. Despite showing great initial promise, the antibiotic trovafloxacin was pulled from the market in the U.S. because of concerns about its toxicity. New research from the University of...

2014-02-27 23:34:46

Cancer prevention awareness and one’s cannabinoid system are the focus of this month’s health update from Publius and The Cannabis Papers: A citizen’s guide to cannabinoids (2011). February's highlighted message on the Bryan William Brickner Blog involves inflammation, the novel cannabinoid receptor GPR55, and their connection to apoptosis, programmed cancer cell death. Chicago, IL (PRWEB) February 27, 2014 “Turning cancer cells off (apoptosis) involves the cannabinoid...

2014-02-26 23:34:39

Cancer-Code Corporation announces the issuance of U.S. Patent No. 8,656,930: “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy." Albuquerque, NM (PRWEB) February 26, 2014 Cancer-Code Corporation (C3) announces the issuance of U.S. Patent No. 8,656,930 on February 25, 2014. The ‘930 patent, entitled “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy,” covers a breakthrough technological approach to...

2014-02-14 08:26:33

Clinical and Regulatory Plans for Two Lead Products Announced SAN DIEGO, Feb. 14, 2014 /PRNewswire/ -- MultiVir, a leader in gene therapies for cancer treatment, presented to the investment community at the Leerink Global Healthcare Conference. Highlights of the presentation included an overview of the development plans for the company's two lead products which are supported by strong pre-clinical and clinical data. MultiVir's adenoviral p53 (Ad-p53) and adenoviral interleukin 24...

2014-02-04 08:35:43

SAN FRANCISCO, February 4, 2014 /PRNewswire/ -- - 36 out of 47 adult subjects (77%) completed the double-blind placebo controlled, multiple dose, crossover study - Primary endpoint met as measured by change from baseline in ADHD-RS-IV score in 5mg (p=0.003) and 10mg (p=0.037) doses which were statistically significantly superior to placebo with approximately 25% greater efficacy compared to placebo -...

2014-01-13 10:39:26

When a tumor is treated with an anti-cancer drug, some cells die and, unfortunately, some cells tend to live. A University of Colorado Cancer Center study published in the journal Nature Cell Biology details a possible difference between the susceptible and resistant cells: the rate at which cells are able to cleanse themselves via the process known as autophagy. “In these studies, say we treat cells with the IC-50 of a drug – at that dose, 50 percent of cells should live and 50...

2014-01-10 11:15:00

A new study led by University of Kentucky researchers suggests that activating the tumor suppressor p53 in normal cells causes them to secrete Par-4, another potent tumor suppressor protein that induces cell death in cancer cells. This finding may help researchers decipher how to inhibit the growth of tumors that have become resistant to other treatments. Loss of the tumor suppressor p53 often contributes to therapy resistance in tumors. In the study, published in Cell Reports, the...

2014-01-08 17:07:21

Walter and Eliza Hall Institute researchers have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells. The discovery offers hope for treating many types of cancer that are driven to grow and spread through the actions of a cancer-causing protein called MYC. Up to 70 per cent of human cancers, including many leukemias and lymphomas, have unusually high levels of MYC, which causes cancerous changes in cells by...

2014-01-07 08:32:13

HEIDELBERG, Germany, Jan. 7, 2014 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today that Thomas Hoeger, Ph.D., Chief Executive Officer, will present the results of the completed phase II efficacy trial in patients with recurrent glioblastoma at the Biotech Showcase(TM) in San Francisco. The presentation will take place on Tuesday, Jan. 14, at 4 p.m. PST at the Parc 55 Wyndham San Francisco - Union Square. "The results of this controlled phase II...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related